Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins - PubMed (original) (raw)
doi: 10.1016/s0166-6851(97)00114-x.
C S Lee, R Bayoumi, A Djimde, O Doumbo, G Swedberg, L D Dao, H Mshinda, M Tanner, W M Watkins, P F Sims, J E Hyde
Affiliations
- PMID: 9364963
- DOI: 10.1016/s0166-6851(97)00114-x
Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins
P Wang et al. Mol Biochem Parasitol. 1997 Nov.
Abstract
Resistance of Plasmodium falciparum to antifolate chemotherapy is a significant problem where combinations such as Fansidar (pyrimethamine-sulfadoxine; PYR-SDX) are used in the treatment of chloroquine-resistant malaria. Antifolate resistance has been associated with variant sequences of dihydrofolate reductase (DHFR) and dihydropteroate synthetase (DHPS), the targets of PYR and SDX respectively. However, while the nature and distribution of mutations in the dhfr gene are well established, this is not yet the case for dhps. We have thus examined by DNA sequence analysis 141 field samples from several geographical regions with differing Fansidar usage (West and East Africa, the Middle East and Viet Nam) to establish a database of the frequency and repertoire of dhps mutations, which were found in 60% of the samples. We have also simultaneously determined from all samples their dhfr sequences, to better understand the relationship of both types of mutation to Fansidar resistance. Whilst the distribution of mutations was quite different across the regions surveyed, it broadly mirrored our understanding of relative Fansidar usage. In samples taken from individual patients before and after drug treatment, we found an association between the more highly mutated forms of dhps and/or dhfr and parasites that were not cleared by antifolate therapy. We also report a novel mutation in a Pakistani sample at position 16 of DHFR (A16S) that is combined with the familiar C59R mutation, but is wild-type at position 108. This is the first observation in a field sample of a mutant dhfr allele where the 108 codon is unchanged.
Similar articles
- High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi.
Bwijo B, Kaneko A, Takechi M, Zungu IL, Moriyama Y, Lum JK, Tsukahara T, Mita T, Takahashi N, Bergqvist Y, Björkman A, Kobayakawa T. Bwijo B, et al. Acta Trop. 2003 Mar;85(3):363-73. doi: 10.1016/s0001-706x(02)00264-4. Acta Trop. 2003. PMID: 12659974 - Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance.
Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA, Estrada-Franco JG, Mollinedo RE, Avila JC, Cespedes JL, Carter D, Doumbo OK. Plowe CV, et al. J Infect Dis. 1997 Dec;176(6):1590-6. doi: 10.1086/514159. J Infect Dis. 1997. PMID: 9395372 - Antifolates can have a role in the treatment of Plasmodium vivax.
Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH. Hawkins VN, et al. Trends Parasitol. 2007 May;23(5):213-22. doi: 10.1016/j.pt.2007.03.002. Epub 2007 Mar 26. Trends Parasitol. 2007. PMID: 17368986 Review.
Cited by
- Sulfadoxine-pyrimethamine impairs Plasmodium falciparum gametocyte infectivity and Anopheles mosquito survival.
Kone A, van de Vegte-Bolmer M, Siebelink-Stoter R, van Gemert GJ, Dara A, Niangaly H, Luty A, Doumbo OK, Sauerwein R, Djimde AA. Kone A, et al. Int J Parasitol. 2010 Aug 15;40(10):1221-8. doi: 10.1016/j.ijpara.2010.05.004. Epub 2010 Jun 2. Int J Parasitol. 2010. PMID: 20515695 Free PMC article. - Temporal trends in prevalence of Plasmodium falciparum drug resistance alleles over two decades of changing antimalarial policy in coastal Kenya.
Okombo J, Kamau AW, Marsh K, Sutherland CJ, Ochola-Oyier LI. Okombo J, et al. Int J Parasitol Drugs Drug Resist. 2014 Aug 7;4(3):152-63. doi: 10.1016/j.ijpddr.2014.07.003. eCollection 2014 Dec. Int J Parasitol Drugs Drug Resist. 2014. PMID: 25516825 Free PMC article. - Host candidate gene polymorphisms and clearance of drug-resistant Plasmodium falciparum parasites.
Diakite M, Achidi EA, Achonduh O, Craik R, Djimde AA, Evehe MS, Green A, Hubbart C, Ibrahim M, Jeffreys A, Khan BK, Kimani F, Kwiatkowski DP, Mbacham WF, Jezan SO, Ouedraogo JB, Rockett K, Rowlands K, Tagelsir N, Tekete MM, Zongo I, Ranford-Cartwright LC. Diakite M, et al. Malar J. 2011 Aug 25;10:250. doi: 10.1186/1475-2875-10-250. Malar J. 2011. PMID: 21867552 Free PMC article. - Monitoring antimalarial drug efficacy: current challenges.
Laufer MK. Laufer MK. Curr Infect Dis Rep. 2009 Jan;11(1):59-65. doi: 10.1007/s11908-009-0009-3. Curr Infect Dis Rep. 2009. PMID: 19094826 Free PMC article. - Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria.
Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF. Triglia T, et al. EMBO J. 1998 Jul 15;17(14):3807-15. doi: 10.1093/emboj/17.14.3807. EMBO J. 1998. PMID: 9669998 Free PMC article.